KKR to Present at the Barclays Financial Services Conference

NEW YORK--(BUSINESS WIRE)-- KKR & Co. Inc. (NYSE: KKR) announced today that Robert H. Lewin, Chief Financial Officer, will present at the Barclays Financial Services Conference on Monday, September 11, 2023 at 12:00 PM ET.

A live webcast of the presentation will be available on the Investor Center section of KKR’s website at https://ir.kkr.com/events-presentations/. For those unable to listen to the live webcast, a replay will be available on the website shortly after the event.

Any questions regarding the webcast may be addressed to KKR’s Investor Relations team at [email protected].

ABOUT KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com and on Twitter @KKR_Co. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230822902666/en/

Investor Relations:
Craig Larson
+1 (877) 610-4910 (U.S.) / +1 (212) 230-9410
[email protected]

Media:
Miles Radcliffe-Trenner or Julia Kosygina
+ 1 (212) 750-8300
[email protected]

Source: KKR & Co. Inc.

You May Also Be Interested In

• Spero Therapeutics shares fall after $105M KKR deal
• Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
• KKR (KKR) PT Lowered to $112 at BMO Capital